BACKGROUND To assess the effectiveness of Shugan Jieyu capsules on peripheral blood miR-124,miR-132,and brain-derived neurotrophic factor(BDNF)levels in patients with mild to moderate depression following coronary art...BACKGROUND To assess the effectiveness of Shugan Jieyu capsules on peripheral blood miR-124,miR-132,and brain-derived neurotrophic factor(BDNF)levels in patients with mild to moderate depression following coronary artery intervention[percuta-neous coronary intervention(PCI)]for coronary heart disease.Patients with mild-to-moderate depression of the liver-qi stagnation type after PCI for coronary heart disease at the 305th Hospital of the People’s Liberation Army were enrolled from June 2022 to November 2023 and randomly assigned to two groups:Experimental(treated with Shugan Jieyu capsules)and control(tr-eated with escitalopram oxalate tablets).This study compared the antidepressant effects of these treatments using 17-item Hamilton Rating Scale for Depression(HAMD-17)scores,metabolic equivalents,low-density lipoprotein cholesterol,BDNF,high-sensitivity C-reactive protein levels,miR-124 and miR-132 levels,distribution of immune-related lymphocyte subsets,and traditional Chinese me-dicine syndrome scores before and after 6 weeks of treatment.RESULTS No significant difference was observed in any index between the two groups before treatment(P>0.05).After treatment,the total efficacy rates were 93.33%and 90.00%in the experimental and control groups,respectively.Experimental group had significantly lower scores for the main and secondary syndromes compared to the control group(P<0.05).No significant difference was observed in the metabolic equivalents between the two groups be-fore and after treatment(P>0.05).The levels of low-density lipoprotein cholesterol,high-sensitivity C-reactive pro-tein,and miR-132 were significantly lower,whereas those of miR-124,BDNF,CD3+T lymphocytes,CD3+CD4+T helper lymphocytes,and CD3+CD4+/CD3+CD8+cells were significantly higher in the experimental group com-pared to the control group(P<0.05).The incidence of adverse reactions during experimental group was signi-ficantly lower than that in control group(P<0.05).CONCLUSION Shugan Jieyu capsules have good efficacy in patients with mild-to-moderate depression after PCI,and its me-chanism may contribute to the regulation of miR-124,miR-132,BDNF levels,and lymphoid immune cells.展开更多
This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagl...This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagle dog plasma. Pharmacokinetic findings were compared among three preparation(lovastatin sustained-release tablet,T p; sustained-release capsule,T J and conventional capsule). Our results showed that the pharmacokinetic parameters in 6 dogs after single-dose oral administration of three perparations were calculated. T max, C max and MRT revealed significant difference (P<0.05). Relative bioavailability was 111.5±16.9 % (T P) and 110.4%±9.6 % (T J). The pharmacokinetic parameters in the 6 dogs after multiple-dose oral administration of three perparations, T max, C max MRT and DF had significant difference (P<0.05); C av , C min and AUC 0-24 h displayed no significant difference (P>0.05). It is concluded that the lovastatin sustained-release tablet and sustained-release capsule are able to maintain a sustained-release for 24 h.展开更多
Objective:To explore effect of bock greenbrier rhizome capsule combined with Fuke Qianjin Tablet on serum inflammatory factors, immune function and hemorheological index in patients with chronic pelvic inflammation.Me...Objective:To explore effect of bock greenbrier rhizome capsule combined with Fuke Qianjin Tablet on serum inflammatory factors, immune function and hemorheological index in patients with chronic pelvic inflammation.Method:A toal of210 cases of patients with chronic pelvic inflammation were divided into control group (n=104) and observation group (n=106) according to random data table method, control group was given Fuke Qianjin Tablet, observation group was given bock greenbrier rhizome capsule on base of control group, treatment period of both groups was 6 weeks. Compared serum inflammatory factors, immune function and hemorheological index in both groups before and after 6 weeks treatment. Results:Before treatment, comparison of inflammatory factors (TNF-α, IL-6 and IL-8), immune function (CD3+, CD4+, CD8+ and CD4+/CD8+) and hemorheological index (low-cut/high-cut whole blood viscosity, plasma viscosity, FIB) in both groups, there was no statistical significant difference;after treatment, TNF-α, IL-6, IL-8, CD8+, low-cut/ high-cut whole blood viscosity, plasma viscosity, FIB level were lower dramatically than pre-treatment intra-group, moreover, these level in observation group after treatment was lower than control group after treatment;CD3+, CD4+ and CD4+/CD8+ level in both groups after treatment was higher than before treatment intra-group, and these levels in observation group after treatment was higher obviously than control group after treatment.Conclusion:Bock greenbrier rhizome capsule combined with Fuke Qianjin Tablet for patients with chronic pelvic inflammation, its regulated effect on serum inflammatory factors, immune function and hemorheological index in patients with chronic pelvic inflammation was superior to only using Fuke Qianjin Tablet, it was worthy of clinical application.展开更多
Objective:To systematically evaluate the clinical efficacy of Kuntai Capsules combined with Diane-35 in the treatment of polycystic ovarian syndrome(PCOS).Methods:The randomized controlled trials(RCTs)of Kuntai Capsul...Objective:To systematically evaluate the clinical efficacy of Kuntai Capsules combined with Diane-35 in the treatment of polycystic ovarian syndrome(PCOS).Methods:The randomized controlled trials(RCTs)of Kuntai Capsules combined with Diane-35 in the treatment of PCOS from databases establishment to April 2020 were searched in Chinese and English databases,and then meta-analysis was performed using RecMan 5.3 software.Results:A total of 132 articles were collected and 14 studies were included.The total sample size was 1254 cases,including 627 cases in the experimental group and 627 cases in the control group.Meta-analysis showed that the combined group was significantly superior to the single group in terms of overall response rate(OR=5.53,95%CI[3.25,9.41],P<0.01),ovulation rate(OR=3.54,95%CI[2.13,5.88],P<0.01),and pregnancy rate(OR=3.21,95%CI[2.00,5.14],P<0.01).In terms of serum sex hormone levels,the combined group was significantly better than the singer group for the regulation of follicle-stimulating hormone(FSH)(MD=-2.09,95%CI[-2.16,-2.01],P<0.01),luteinizing hormone(LH)(MD=-2.15,95%CI[-2.35,-1.95],P<0.01),estrogen(E2)(MD=36.47,95%CI[34.97,37.96],P<0.01),and testosterone(T)(MD=-1.95,95%CI[-2.77,-1.14],P<0.01).In addition,the combined group also showed some advantages over the single group in improving the level of insulin resistance(HOMA-IR)and pancreatic beta cells function(HOMA-β).Conclusion:Kuntai Capsules combined with Diane-35 had certain efficacy advantage in the treatment of PCOS compared with control group.However,the data indicate that the methodological quality of the studies are low,there was potential publication bias,no define conclusion could be drawn,and more high-quality RCTs studies are needed for further validation.展开更多
Objective:We used doxorubicin(DOX)-induced heart failure mouse model to investigate the therapeutic effect and involved mechanism of XianGui capsule(XG)combined with Sacubitril Valsartan Sodium tablets(LCZ696)on heart...Objective:We used doxorubicin(DOX)-induced heart failure mouse model to investigate the therapeutic effect and involved mechanism of XianGui capsule(XG)combined with Sacubitril Valsartan Sodium tablets(LCZ696)on heart failure.Methods:C57BL/6 mice were divided into control(Ctrl)group,DOX group,XG group,LCZ696 group and combination(XL)group.After the administration,mice heart functions,blood pressure,and serum cardiac injury markers were detected.Heart sections were conducted with HE,Sirius Red and immunohistochemical staining.The heart tissues were collected for the determination of protein or mRNA expression of anti oxidative,fibrosis,inflammation and apoptosis-related genes by Western Blot and qRT-PCR.Results:XG,LCZ696 or XG plus LCZ696 can significantly improve the heart functions of mice,reduce the expression of cardiac injury markers,and inhibit myocardial fibrosis.Mechanically,XG,LCZ696 or their co treatment antagonized myocardial apoptosis,increase forkhead box O3a,superoxide dismutase 2(SOD2)protein,SOD1,catalase mRNA expressions and inhibited the protein and mRNA levels of toll-like 4,nuclear factorkB,and inflammatory cytokines.Conclusion:XG,LCZ696 or XG plus LCZ696 decreases DOX-induced cardiomyocytes apoptosis by reducing inflammatory factors and enhancing expression of antioxidant enzymes,thereby alleviating the development of heart failure.展开更多
脉血康胶囊(肠溶片)治疗心脑血管疾病具有良好的临床疗效及安全性。在临床医生问卷调查和脉血康胶囊(肠溶片)研究文献系统回顾的基础上,采用国际临床医学专家共识研制方法,基于现有最佳证据,充分结合专家经验,遵循“循证为主,共识为辅,...脉血康胶囊(肠溶片)治疗心脑血管疾病具有良好的临床疗效及安全性。在临床医生问卷调查和脉血康胶囊(肠溶片)研究文献系统回顾的基础上,采用国际临床医学专家共识研制方法,基于现有最佳证据,充分结合专家经验,遵循“循证为主,共识为辅,经验为鉴”的原则,国内26位中西医临床、药学、方法学等多学科专家共同研制该共识,旨在进一步提高临床医生对该药的认识,更好地指导其临床合理用药。共识采用国际公认的证据分级推荐标准即评估、发展和评价建议的分级(Grading of Recommendations Assessment,Development and Evaluation,GRADE分级),如果证据充分则形成“推荐意见”,采用GRADE网格计票规则;如果证据不充分,则形成“共识建议”,采用多数计票规则。共识对脉血康胶囊(肠溶片)用于心脑血管疾病的适应证、用法用量、疗程、禁忌证、合并用药进行了推荐或建议,并完善了安全性信息,为其临床的合理使用提供参考。展开更多
基金the 305 Hospital Independent Scientific Research Fund,2024,No.24ZZJJLW-022.
文摘BACKGROUND To assess the effectiveness of Shugan Jieyu capsules on peripheral blood miR-124,miR-132,and brain-derived neurotrophic factor(BDNF)levels in patients with mild to moderate depression following coronary artery intervention[percuta-neous coronary intervention(PCI)]for coronary heart disease.Patients with mild-to-moderate depression of the liver-qi stagnation type after PCI for coronary heart disease at the 305th Hospital of the People’s Liberation Army were enrolled from June 2022 to November 2023 and randomly assigned to two groups:Experimental(treated with Shugan Jieyu capsules)and control(tr-eated with escitalopram oxalate tablets).This study compared the antidepressant effects of these treatments using 17-item Hamilton Rating Scale for Depression(HAMD-17)scores,metabolic equivalents,low-density lipoprotein cholesterol,BDNF,high-sensitivity C-reactive protein levels,miR-124 and miR-132 levels,distribution of immune-related lymphocyte subsets,and traditional Chinese me-dicine syndrome scores before and after 6 weeks of treatment.RESULTS No significant difference was observed in any index between the two groups before treatment(P>0.05).After treatment,the total efficacy rates were 93.33%and 90.00%in the experimental and control groups,respectively.Experimental group had significantly lower scores for the main and secondary syndromes compared to the control group(P<0.05).No significant difference was observed in the metabolic equivalents between the two groups be-fore and after treatment(P>0.05).The levels of low-density lipoprotein cholesterol,high-sensitivity C-reactive pro-tein,and miR-132 were significantly lower,whereas those of miR-124,BDNF,CD3+T lymphocytes,CD3+CD4+T helper lymphocytes,and CD3+CD4+/CD3+CD8+cells were significantly higher in the experimental group com-pared to the control group(P<0.05).The incidence of adverse reactions during experimental group was signi-ficantly lower than that in control group(P<0.05).CONCLUSION Shugan Jieyu capsules have good efficacy in patients with mild-to-moderate depression after PCI,and its me-chanism may contribute to the regulation of miR-124,miR-132,BDNF levels,and lymphoid immune cells.
文摘This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagle dog plasma. Pharmacokinetic findings were compared among three preparation(lovastatin sustained-release tablet,T p; sustained-release capsule,T J and conventional capsule). Our results showed that the pharmacokinetic parameters in 6 dogs after single-dose oral administration of three perparations were calculated. T max, C max and MRT revealed significant difference (P<0.05). Relative bioavailability was 111.5±16.9 % (T P) and 110.4%±9.6 % (T J). The pharmacokinetic parameters in the 6 dogs after multiple-dose oral administration of three perparations, T max, C max MRT and DF had significant difference (P<0.05); C av , C min and AUC 0-24 h displayed no significant difference (P>0.05). It is concluded that the lovastatin sustained-release tablet and sustained-release capsule are able to maintain a sustained-release for 24 h.
文摘Objective:To explore effect of bock greenbrier rhizome capsule combined with Fuke Qianjin Tablet on serum inflammatory factors, immune function and hemorheological index in patients with chronic pelvic inflammation.Method:A toal of210 cases of patients with chronic pelvic inflammation were divided into control group (n=104) and observation group (n=106) according to random data table method, control group was given Fuke Qianjin Tablet, observation group was given bock greenbrier rhizome capsule on base of control group, treatment period of both groups was 6 weeks. Compared serum inflammatory factors, immune function and hemorheological index in both groups before and after 6 weeks treatment. Results:Before treatment, comparison of inflammatory factors (TNF-α, IL-6 and IL-8), immune function (CD3+, CD4+, CD8+ and CD4+/CD8+) and hemorheological index (low-cut/high-cut whole blood viscosity, plasma viscosity, FIB) in both groups, there was no statistical significant difference;after treatment, TNF-α, IL-6, IL-8, CD8+, low-cut/ high-cut whole blood viscosity, plasma viscosity, FIB level were lower dramatically than pre-treatment intra-group, moreover, these level in observation group after treatment was lower than control group after treatment;CD3+, CD4+ and CD4+/CD8+ level in both groups after treatment was higher than before treatment intra-group, and these levels in observation group after treatment was higher obviously than control group after treatment.Conclusion:Bock greenbrier rhizome capsule combined with Fuke Qianjin Tablet for patients with chronic pelvic inflammation, its regulated effect on serum inflammatory factors, immune function and hemorheological index in patients with chronic pelvic inflammation was superior to only using Fuke Qianjin Tablet, it was worthy of clinical application.
基金National key research and deve lopment planning(No.2018YFC1003900)。
文摘Objective:To systematically evaluate the clinical efficacy of Kuntai Capsules combined with Diane-35 in the treatment of polycystic ovarian syndrome(PCOS).Methods:The randomized controlled trials(RCTs)of Kuntai Capsules combined with Diane-35 in the treatment of PCOS from databases establishment to April 2020 were searched in Chinese and English databases,and then meta-analysis was performed using RecMan 5.3 software.Results:A total of 132 articles were collected and 14 studies were included.The total sample size was 1254 cases,including 627 cases in the experimental group and 627 cases in the control group.Meta-analysis showed that the combined group was significantly superior to the single group in terms of overall response rate(OR=5.53,95%CI[3.25,9.41],P<0.01),ovulation rate(OR=3.54,95%CI[2.13,5.88],P<0.01),and pregnancy rate(OR=3.21,95%CI[2.00,5.14],P<0.01).In terms of serum sex hormone levels,the combined group was significantly better than the singer group for the regulation of follicle-stimulating hormone(FSH)(MD=-2.09,95%CI[-2.16,-2.01],P<0.01),luteinizing hormone(LH)(MD=-2.15,95%CI[-2.35,-1.95],P<0.01),estrogen(E2)(MD=36.47,95%CI[34.97,37.96],P<0.01),and testosterone(T)(MD=-1.95,95%CI[-2.77,-1.14],P<0.01).In addition,the combined group also showed some advantages over the single group in improving the level of insulin resistance(HOMA-IR)and pancreatic beta cells function(HOMA-β).Conclusion:Kuntai Capsules combined with Diane-35 had certain efficacy advantage in the treatment of PCOS compared with control group.However,the data indicate that the methodological quality of the studies are low,there was potential publication bias,no define conclusion could be drawn,and more high-quality RCTs studies are needed for further validation.
基金This work was supported by the National Natural Science Foundation of China(No.81722046)the China Postdoctoral Science Foundation Grants(No.2020M681914)the Fundamental Research Funds for the Central Universities to X Yang,Y Duan and Y Chen.
文摘Objective:We used doxorubicin(DOX)-induced heart failure mouse model to investigate the therapeutic effect and involved mechanism of XianGui capsule(XG)combined with Sacubitril Valsartan Sodium tablets(LCZ696)on heart failure.Methods:C57BL/6 mice were divided into control(Ctrl)group,DOX group,XG group,LCZ696 group and combination(XL)group.After the administration,mice heart functions,blood pressure,and serum cardiac injury markers were detected.Heart sections were conducted with HE,Sirius Red and immunohistochemical staining.The heart tissues were collected for the determination of protein or mRNA expression of anti oxidative,fibrosis,inflammation and apoptosis-related genes by Western Blot and qRT-PCR.Results:XG,LCZ696 or XG plus LCZ696 can significantly improve the heart functions of mice,reduce the expression of cardiac injury markers,and inhibit myocardial fibrosis.Mechanically,XG,LCZ696 or their co treatment antagonized myocardial apoptosis,increase forkhead box O3a,superoxide dismutase 2(SOD2)protein,SOD1,catalase mRNA expressions and inhibited the protein and mRNA levels of toll-like 4,nuclear factorkB,and inflammatory cytokines.Conclusion:XG,LCZ696 or XG plus LCZ696 decreases DOX-induced cardiomyocytes apoptosis by reducing inflammatory factors and enhancing expression of antioxidant enzymes,thereby alleviating the development of heart failure.
文摘脉血康胶囊(肠溶片)治疗心脑血管疾病具有良好的临床疗效及安全性。在临床医生问卷调查和脉血康胶囊(肠溶片)研究文献系统回顾的基础上,采用国际临床医学专家共识研制方法,基于现有最佳证据,充分结合专家经验,遵循“循证为主,共识为辅,经验为鉴”的原则,国内26位中西医临床、药学、方法学等多学科专家共同研制该共识,旨在进一步提高临床医生对该药的认识,更好地指导其临床合理用药。共识采用国际公认的证据分级推荐标准即评估、发展和评价建议的分级(Grading of Recommendations Assessment,Development and Evaluation,GRADE分级),如果证据充分则形成“推荐意见”,采用GRADE网格计票规则;如果证据不充分,则形成“共识建议”,采用多数计票规则。共识对脉血康胶囊(肠溶片)用于心脑血管疾病的适应证、用法用量、疗程、禁忌证、合并用药进行了推荐或建议,并完善了安全性信息,为其临床的合理使用提供参考。
